Soligenix, Inc. · NASDAQ:SNGX
Soligenix — Investor Presentation (April 2012)
25 slides from Soligenix's investor presentation, Apr 5, 2012
Slide 1: Soligenix
((SOLIGENIX OTC BB: SNGX
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words "expects," “anticipates,” "believes," "intends," "estimates," "plans," "will," “outlook” and simil
Slide 3: Soligenix
Soligenix Soligenix, Inc. is a development stage, publically-traded, biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, as well as vaccine technology in the areas of biodefense and infectious disease
Slide 4: Corporate Value Proposition
Corporate BioTherapeutics Vaccines/ BioDefense Value Proposition + Diversified portfolio: BioTherapeutics and Vaccines/BioDefense + Multiple programs in rare disease and areas of unmet medical need + Significant NIH/FDA grant support for most programs + Experienced management and board of directors
Slide 5: Senior Management Team
Senior Management Team + 23 years of experience + Discovery Laboratories, Inc. (COO) ‘Acute Therapeutics, Inc. (Co-Founder) Ohmeda PPD, Inc. The Liposome Company, Inc. Wyeth Ayerst Christopher J. Schaber, PhD. President & CEO + 29 years of experience Robert Brey, PhD + Lederle-Praxis, division of Am
Slide 6: Independent Board Directors
Independent Board Directors +35 years of experience Keith Brownlie, CPA Rooerevame +31 yeats of experience Tamar Howson, MBA, =BristokMyers Squibb «SmithKline Beecham Corporation +20 yeats of experience + Sigma-Tau Pharmaceuticals, Ine + AstenJohnson, Inc + Price Waterhouse Coopers Gregg Lapointe, C
Slide 7: BioTherapeutics Pipeline
BioTherapeutics Pipeline Preclinical Phase 1 Phase 2 Phase 3 'SGX201 Radiation Enteritis 'SGX203 Pediatric Crohn’s Disease orBec™ ‘Treatment of Acute GI GVHD ‘orBec® Prevention of Acute GVHD orBec® ‘Treatment of Chronic GI GVHD __ | a a | [PM™ Leuprolide Prostate Cancer/Endometriosis Vaccines/BioDef
Slide 8: BioTherapeutics
BioTherapeutics SOLIGENIX, °
Slide 9: Oral Beclomethasone Dipropionate
Oral Beclomethasone Dipropionate * Oral Beclomethasone Dipropionate (BDP) — Potent, topically active, anti- inflammatory steroid - Designed to treat inflammation within lining of GI tract + Strategy is to decrease need for prolonged use of high dose systemic prednisone - Superior safety profile comp
Slide 10: SGX201 - Acute Radiation Enteritis
SGX201 - Acute Radiation Enteritis * Block inflammatory component of acute radiation enteritis in Gl tract in rectal cancer patients receiving radiation therapy Oneertnl * Acute radiation enteritis affects over 100,000 rectal cancer patients world pportunity wide annually + No approved therapies; ar
Slide 11: SGX203 - Pediatric Crohn's Disease
SGX203 - Pediatric Crohn’s Disease + Inflammation that can affect Gl tract from the mouth to the colon * Over 200,000 children/adolescents with Crohn's disease worldwide — 50% have disease proximal to terminal ileum + ~ 80% treated with steroids off-label as first-line therapy; adrenal suppression a
Slide 12: SGX203 - Targeted Approach to GI Inflammation
SGX203 - Targeted Approach to GI Inflammation Two-Pill System + Each tablet contains 1 mg BDP + 1 Immediate Release (IR) tablet designed to release in the upper G' 1 Delayed Release (DR) tablet designed to release in the lower Gl tract tract and Diagram showing dispersion of IR tablet in the stomach
Slide 13: Vaccine/BioDefense
Vaccine/BioDefense att Addressing Critical Concerns for Industry and Government
Slide 14: Vaccines/BioDefense Business Model
Vaccines/BioDefense Business Model Soligenix Vaccine BioDefense Division SOLIGENIX
Slide 15: ThermoVax Vaccine Thermostability Platform
ThermoVax™ Vaccine Thermostability Platform Opportunity ThermoVax™ Profile Development Plan + World Health Organization reports 50% of all vaccine doses globally are wasted due to excursions from required cold chain temperature ranges + Aluminum-adjuvanted vaccines often require strict adherence to
Slide 16: ThermoVax - Proof of Concept Data
ThermoVax™ - Proof of Concept Data Positive results to date Physical parameters RiVax™ Incubation 0 days week 1Month Freeze Dried. ac 100%. 100% 100% 40°C 100% 100% 100% Liquid Suspension | 4°C 100% 57% <20% 40°C 100% <10% <10% Immunogenicity RiVax™ O days week 1 month Freeze Dried Control potency |
Slide 17: Anthrax — Evolution Of Threat
Anthrax — Evolution Of Threat 2007 — Confirmed al-Qaeda interest in anthrax development at Tribunal Hearing 2007 — Anthrax highlighted in FBI terrorism report as top bioterror threat along with ricin 2001 - Anthrax attacks via US mail — 5 people dead 1998 — U.S. Secretary of Defense William Cohen ap
Slide 18: SGX204 — Anthrax Vaccine Opportunity
Opportunity SGX204 Profile Development Plan SGX204 — Anthrax Vaccine + Category A countermeasures against anthrax exposure clear interest to UsMWorld governments + More than $4 billion spent to date on vaccines and therapeutics with recent proposal request by BARDA indicating continued area of unmet
Slide 19: SGX202 — GI Acute Radiation Syndrome
SGX202 — GI Acute Radiation Syndrome + Category A countermeasures against radiation exposure of clear interest to US/World governments CU NE ° More than $600 million spent to date on therapeutics against radiation injury with recent funding activity indicating continued area of unmet medical need +
Slide 20: GI Recovery from Acute Radiation Injury
GI Recovery from Acute Radiation Injury in Established Beagle Dog Model Survival after 12 Gy TBI (0.7 Gy/min) Treatment Group Median p value vs. Survival control Controls 8 days SGX202 6 100 days 0.04 (2 HR after TBI) SGXx202 6 87 days* 0.048 (24 HR after TBI) * ongoing; 2 dogs still on study at Fre
Slide 21: Ricin — Evolution Of A Threat
Ricin — Evolution Of A Threat 2011 - al-Qaeda of Yemen threat to use ricin around explosive devices 2010 - al-Qaeda threat to poison food supplies with ricin toxin and cyanide 2008 - Roger Bergendorff in coma after ricin exposure in Las Vegas Motel 2007- Ricin highlighted in FBI terrorism report as
Slide 22: RiVax — Ricin Toxin Vaccine
RiVax™ — Ricin Toxin Vaccine + Category B countermeasures against ricin exposure of rising interest by US government due to recent Terrorist threats and ease of castor bean procurement and production + Interest evidenced by DoD's recent RFI for vaccines against ricin exposure entitled, “Development
Slide 23: Worldwide Market Potential
Worldwide Market Potential 500 4 $500 450 4 $450 Assumptions Pediatric Crohn's Disease 400+ 80,000 Patients US 80,000 Patients EU % 350+ Acute Ralaton Entertis 300 50,000 Patients US & 300 50,000 Paints EU S 2504 Assumes 2 sublicense $200 deals ee 200 $175 rill ssumes 3 year 150 procurement order of
Slide 24: Milestone Events - Past & Future
Milestone Events - Past & Future ¥+ Execution of ThermoVax"™ vaccine thermostability license with UC - subject of $9.4 million NIH grant 2011 ¥+ Completed $30 million EU partnership with Sigma-Tau for orBec® ¥;* Positive results of SGX202 in preclinical model of GI ARS + Stopped enrollment following
Slide 25: Thank You
THANK YOU